4/A//SEC Filing
Gibbs Michael Terrence 4/A
Accession 0000899243-22-012511
CIK 0001492674other
Filed
Mar 27, 8:00 PM ET
Accepted
Mar 28, 6:34 PM ET
Size
11.7 KB
Accession
0000899243-22-012511
Insider Transaction Report
Form 4/AAmended
Gibbs Michael Terrence
General Counsel
Transactions
- Tax Payment
Common Stock
2022-02-21$0.47/sh−5,275$2,458→ 79,923 total - Exercise/Conversion
Common Stock
2022-02-21+10,000→ 85,198 total - Award
Restricted Stock Units
2022-02-20+600,000→ 600,000 total→ Common Stock (600,000 underlying) - Exercise/Conversion
Restricted Stock Units
2022-02-21−10,000→ 0 total→ Common Stock (10,000 underlying)
Footnotes (7)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]Includes 1,942 shares acquired under the Issuer's employee stock purchase plan ("ESPP") on May 15, 2021.
- [F3]The Form 4, as originally filed, incorrectly reported the amount of beneficially owned securities as 75,198
- [F4]5,275 shares of common stock were automatically withheld at vesting to cover required tax withholding.
- [F5]The Form 4, as originally filed, incorrectly reported the amount of beneficially owned securities as 69,923
- [F6]On February 20, 2022 the reporting person was granted 600,000 RSU's that vest in three equal annual installments commencing on February 20, 2023.
- [F7]On February 21, 2019 the reporting person was granted 30,000 RSU's that vest in three equal annual installments beginning on February 21, 2020.
Documents
Issuer
T2 Biosystems, Inc.
CIK 0001492674
Entity typeother
Related Parties
1- filerCIK 0001665000
Filing Metadata
- Form type
- 4/A
- Filed
- Mar 27, 8:00 PM ET
- Accepted
- Mar 28, 6:34 PM ET
- Size
- 11.7 KB